{"id":1002438,"date":"2026-09-10T09:52:44","date_gmt":"2026-09-10T13:52:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/"},"modified":"2026-09-10T09:52:44","modified_gmt":"2026-09-10T13:52:44","slug":"vistagen-to-present-at-psych-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/","title":{"rendered":"Vistagen to Present at Psych Congress 2026"},"content":{"rendered":"<h2>\nPoster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Sept.  10, 2026  (GLOBE NEWSWIRE) &#8212; Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026.<\/p>\n<p>\n        <strong><br \/>\n          <u>Poster Presentation<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Date:<\/strong> Thursday, September 17, 2026, and Friday, September 18, 2026 <br \/><strong>Title:<\/strong> Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores \u226595: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials<br \/><strong>Authors: <\/strong>Azmi Nasser, PhD, Michael R. Liebowitz, MD, Aubrey Reid, MS, Imogene Dunn, PhD, Eric Davis, MD, Ross A. Baker, PhD, Angel Angelov, MD, Louis Monti, MD, PhD<br \/><strong>Poster Number:<\/strong> 230<\/p>\n<p>\n        <strong>About Vistagen<\/strong><br \/>\n        <br \/>Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen\u2019s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen\u2019s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nZLfoKzU9u2pEbkUKv7JZbT-jCOz8y8DQxStaulfaLncbhevWjTbYyRE10exXm7mnmRN3hm6p_CRL27FULyrvJ8kYThl08tHjnq1nbRhqldnPsMqEN9ecE_8ispJ8_OR3ibPRczu7cplAjToNPptbDHEZpwVIKI9bICO-dz7Yjy1CMqHrVQI7wDMT-tiAL-Z1GMWUHC7xsDjrgthAsowYh0wSe7HGCaVeG4MbN4yFRm6-xitm9xhRqqdmK6fi3nV1GZ8p-NV4W0Bhn3zr03wsw==\" rel=\"nofollow\" target=\"_blank\">www.Vistagen.com<\/a><\/p>\n<p>\n        <strong>Investor Inquiries:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-TpZFN8DBeEQauTHKzYhzfelTcc0_pZpl7cGezLzeZdOIYXYoiig2ROCXQG9TOsoHJCV-2S4MXOCrfotRlOQ8w==\" rel=\"nofollow\" target=\"_blank\">IR@vistagen.com<\/a>\n      <\/p>\n<p>\n        <strong>Media Inquiries:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jSEdIIZMSDoYW5sUrpdemaAeTljTkfRfOkldutUU97xptE36OWz1OWs4SJHvrhNA6WkbSPttMnMltpqN3E0P3j0w40YVupweHHqwrJjuQD0=\" rel=\"nofollow\" target=\"_blank\">media@vistagen.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmVjZDYwMzktMWFlZC00OTM5LWJjODUtMTdjNjhhZDc0NGJjLTEyMTU5MzUtMjAyNi0wOS0xMC1lbg==\/tiny\/Vistagen-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026. Poster Presentation Date: Thursday, September 17, 2026, and Friday, September 18, 2026 Title: Fasedienol Nasal Spray for Acute Treatment of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vistagen to Present at Psych Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002438","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vistagen to Present at Psych Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vistagen to Present at Psych Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026. Poster Presentation Date: Thursday, September 17, 2026, and Friday, September 18, 2026 Title: Fasedienol Nasal Spray for Acute Treatment of &hellip; Continue reading &quot;Vistagen to Present at Psych Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T13:52:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vistagen to Present at Psych Congress 2026\",\"datePublished\":\"2026-09-10T13:52:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/\",\"name\":\"Vistagen to Present at Psych Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\",\"datePublished\":\"2026-09-10T13:52:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-to-present-at-psych-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vistagen to Present at Psych Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vistagen to Present at Psych Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Vistagen to Present at Psych Congress 2026 - Market Newsdesk","og_description":"Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) &#8212; Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026. Poster Presentation Date: Thursday, September 17, 2026, and Friday, September 18, 2026 Title: Fasedienol Nasal Spray for Acute Treatment of &hellip; Continue reading \"Vistagen to Present at Psych Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-10T13:52:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vistagen to Present at Psych Congress 2026","datePublished":"2026-09-10T13:52:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/","name":"Vistagen to Present at Psych Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=","datePublished":"2026-09-10T13:52:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDMwMiM3ODI2NDY5IzIyMDQzODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-to-present-at-psych-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vistagen to Present at Psych Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002438"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}